Citi Calls Olema Drop After AstraZeneca Trial Miss a Buying Opportunity
Citi calls Olema’s drop after AstraZeneca’s SERENA-4 miss excessive, keeps Buy and $59 target, and sees $20 value from later-line use.
/ 5 items
#OLMA↓
H.C. Wainwright: Roche’s “Disappointing” persevERA Failure Is Not a Full Read-Through for Olema
H.C. Wainwright calls Roche’s persevERA trial disappointing but says it’s not a full readthrough for Olema Oncology. Different CDK4/6 inhibitor (ribociclib) may favor palazestrant in OPERA-02.
Jefferies Boosts Olema Oncology Price Target on Strong SERD Momentum
Jefferies raises Olema Oncology’s price target to $43 as new Roche giredestrant data strengthens confidence in next-generation SERDs and multibillion-dollar market potential.
Roche's Giredestrant Success: Cutting Breast Cancer Recurrence Risk
Roche’s experimental SERD, giredestrant, showed unprecedented success in a late-stage trial, cutting recurrence risk in early-stage, ER-positive breast cancer.
Olema Stock Crashes on Roche's Shadow, Not Its Own Data
Despite positive palazestrant (OP-1250) trial results, Olema Pharmaceuticals' shares dropped Monday, overshadowed by disappointing outcomes from a Roche breast cancer study.